Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Multiple Myeloma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(424)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
carfilzomib
Sensitive: A1 - Approval
carfilzomib
Sensitive
:
A1
carfilzomib
Sensitive: A1 - Approval
carfilzomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + panobinostat
Sensitive: A1 - Approval
bortezomib + panobinostat
Sensitive
:
A1
bortezomib + panobinostat
Sensitive: A1 - Approval
bortezomib + panobinostat
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
Sensitive: A1 - Approval
Sensitive
:
A1
Sensitive: A1 - Approval
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
ciltacabtagene autoleucel
Sensitive: A1 - Approval
ciltacabtagene autoleucel
Sensitive
:
A1
ciltacabtagene autoleucel
Sensitive: A1 - Approval
ciltacabtagene autoleucel
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide
Sensitive: A1 - Approval
pomalidomide
Sensitive
:
A1
pomalidomide
Sensitive: A1 - Approval
pomalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
thalidomide
Sensitive: A1 - Approval
thalidomide
Sensitive
:
A1
thalidomide
Sensitive: A1 - Approval
thalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive: A1 - Approval
isatuximab-irfc
Sensitive
:
A1
isatuximab-irfc
Sensitive: A1 - Approval
isatuximab-irfc
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
prednisone + thalidomide + melphalan
Sensitive: A1 - Approval
prednisone + thalidomide + melphalan
Sensitive
:
A1
prednisone + thalidomide + melphalan
Sensitive: A1 - Approval
prednisone + thalidomide + melphalan
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
lenalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
lenalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
lenalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: A1 - Approval
lenalidomide + elotuzumab
Sensitive
:
A1
lenalidomide + elotuzumab
Sensitive: A1 - Approval
lenalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + daratumumab
Sensitive: A1 - Approval
lenalidomide + daratumumab
Sensitive
:
A1
lenalidomide + daratumumab
Sensitive: A1 - Approval
lenalidomide + daratumumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
selinexor
Sensitive: A1 - Approval
selinexor
Sensitive
:
A1
selinexor
Sensitive: A1 - Approval
selinexor
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + ixazomib
Sensitive: A1 - Approval
lenalidomide + ixazomib
Sensitive
:
A1
lenalidomide + ixazomib
Sensitive: A1 - Approval
lenalidomide + ixazomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
daratumumab and hyaluronidase-fihj
Sensitive
:
A1
daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
daratumumab and hyaluronidase-fihj
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
Sensitive: A1 - Approval
Sensitive
:
A1
Sensitive: A1 - Approval
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
belantamab mafodotin-blmf
Sensitive: A1 - Approval
belantamab mafodotin-blmf
Sensitive
:
A1
belantamab mafodotin-blmf
Sensitive: A1 - Approval
belantamab mafodotin-blmf
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
denosumab
Sensitive: A1 - Approval
denosumab
Sensitive
:
A1
denosumab
Sensitive: A1 - Approval
denosumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
melphalan flufenamide
Sensitive: A1 - Approval
melphalan flufenamide
Sensitive
:
A1
melphalan flufenamide
Sensitive: A1 - Approval
melphalan flufenamide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + isatuximab-irfc
Sensitive: A1 - Approval
pomalidomide + isatuximab-irfc
Sensitive
:
A1
pomalidomide + isatuximab-irfc
Sensitive: A1 - Approval
pomalidomide + isatuximab-irfc
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + carfilzomib
Sensitive: A1 - Approval
lenalidomide + carfilzomib
Sensitive
:
A1
lenalidomide + carfilzomib
Sensitive: A1 - Approval
lenalidomide + carfilzomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
daratumumab + pomalidomide
Sensitive: A1 - Approval
daratumumab + pomalidomide
Sensitive
:
A1
daratumumab + pomalidomide
Sensitive: A1 - Approval
daratumumab + pomalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
daratumumab
Sensitive: A1 - Approval
daratumumab
Sensitive
:
A1
daratumumab
Sensitive: A1 - Approval
daratumumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
idecabtagene vicleucel
Sensitive: A1 - Approval
idecabtagene vicleucel
Sensitive
:
A1
idecabtagene vicleucel
Sensitive: A1 - Approval
idecabtagene vicleucel
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
zoledronic acid
Sensitive: A1 - Approval
zoledronic acid
Sensitive
:
A1
zoledronic acid
Sensitive: A1 - Approval
zoledronic acid
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
daratumumab + thalidomide
Sensitive: A1 - Approval
daratumumab + thalidomide
Sensitive
:
A1
daratumumab + thalidomide
Sensitive: A1 - Approval
daratumumab + thalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
thalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
thalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
thalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
thalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
pomalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
pomalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
pomalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
